Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Plugs Away On Repatha, With Hope For New Monthly Product

Executive Summary

In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.

Advertisement

Related Content

Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public
Repatha Monthly Dose Approved With On-Body Pushtronex System
Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex
Regeneron: PCSK9s Drowning In Paperwork
PCSK9 Sponsors, Payers In The Ring At ACC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register